TY - JOUR
T1 - Cerebral multimodality monitoring in adult neurocritical care patients with acute brain injury: A narrative review
AU - Tas, J.
AU - Czosnyka, M.
AU - van der Horst, I.C.C.
AU - Park, S.
AU - van Heugten, C.
AU - Sekhon, M.
AU - Robba, C.
AU - Menon, D.K.
AU - Zeiler, F.A.
AU - Aries, M.J.H.
N1 - Funding Information:
FZ research and laboratory is supported by the Manitoba Public Insurance (MPI) Neuroscience Research Endowment/Operating Fund, Health Sciences Centre Foundation—Winnipeg, Rudy Falk Clinician Scientist Professorship, various granting opportunities at the University of Manitoba, Research Manitoba, National Institutes of Health (NIH) and the Canada Foundation for Innovation (CFI). MA and JT are supported by a grant from the “Brain Battle” Foundation (HersenStrijd fonds) from the University Maastricht, Netherlands. DM is supported by an NIHR Senior Investigator Award. MC is supported by NIHR BRC.
Publisher Copyright:
Copyright © 2022 Tas, Czosnyka, van der Horst, Park, van Heugten, Sekhon, Robba, Menon, Zeiler and Aries.
PY - 2022/12/1
Y1 - 2022/12/1
N2 - Cerebral multimodality monitoring (MMM) is, even with a general lack of Class I evidence, increasingly recognized as a tool to support clinical decision-making in the neuroscience intensive care unit (NICU). However, literature and guidelines have focused on unimodal signals in a specific form of acute brain injury. Integrating unimodal signals in multiple signal monitoring is the next step for clinical studies and patient care. As such, we aimed to investigate the recent application of MMM in studies of adult patients with traumatic brain injury (TBI), subarachnoid hemorrhage (SAH), intracerebral hemorrhage (ICH), acute ischemic stroke (AIS), and hypoxic ischemic brain injury following cardiac arrest (HIBI). We identified continuous or daily updated monitoring modalities and summarized the monitoring setting, study setting, and clinical characteristics. In addition, we discussed clinical outcome in intervention studies. We identified 112 MMM studies, including 11 modalities, over the last 7 years (2015-2022). Fifty-eight studies (52%) applied only two modalities. Most frequently combined were ICP monitoring (92 studies (82%)) together with PbtO(2) (63 studies (56%). Most studies included patients with TBI (59 studies) or SAH (53 studies). The enrollment period of 34 studies (30%) took more than 5 years, whereas the median sample size was only 36 patients (q1- q3, 20-74). We classified studies as either observational (68 studies) or interventional (44 studies). The interventions were subclassified as systemic (24 studies), cerebral (10 studies), and interventions guided by MMM (11 studies). We identified 20 different systemic or cerebral interventions. Nine (9/11, 82%) of the MMM-guided studies included clinical outcome as an endpoint. In 78% (7/9) of these MMM-guided intervention studies, a significant improvement in outcome was demonstrated in favor of interventions guided by MMM. Clinical outcome may be improved with interventions guided by MMM. This strengthens the belief in this application, but further interdisciplinary collaborations are needed to overcome the heterogeneity, as illustrated in the present review. Future research should focus on increasing sample sizes, improved data collection, refining definitions of secondary injuries, and standardized interventions. Only then can we proceed with complex outcome studies with MMM-guided treatment.
AB - Cerebral multimodality monitoring (MMM) is, even with a general lack of Class I evidence, increasingly recognized as a tool to support clinical decision-making in the neuroscience intensive care unit (NICU). However, literature and guidelines have focused on unimodal signals in a specific form of acute brain injury. Integrating unimodal signals in multiple signal monitoring is the next step for clinical studies and patient care. As such, we aimed to investigate the recent application of MMM in studies of adult patients with traumatic brain injury (TBI), subarachnoid hemorrhage (SAH), intracerebral hemorrhage (ICH), acute ischemic stroke (AIS), and hypoxic ischemic brain injury following cardiac arrest (HIBI). We identified continuous or daily updated monitoring modalities and summarized the monitoring setting, study setting, and clinical characteristics. In addition, we discussed clinical outcome in intervention studies. We identified 112 MMM studies, including 11 modalities, over the last 7 years (2015-2022). Fifty-eight studies (52%) applied only two modalities. Most frequently combined were ICP monitoring (92 studies (82%)) together with PbtO(2) (63 studies (56%). Most studies included patients with TBI (59 studies) or SAH (53 studies). The enrollment period of 34 studies (30%) took more than 5 years, whereas the median sample size was only 36 patients (q1- q3, 20-74). We classified studies as either observational (68 studies) or interventional (44 studies). The interventions were subclassified as systemic (24 studies), cerebral (10 studies), and interventions guided by MMM (11 studies). We identified 20 different systemic or cerebral interventions. Nine (9/11, 82%) of the MMM-guided studies included clinical outcome as an endpoint. In 78% (7/9) of these MMM-guided intervention studies, a significant improvement in outcome was demonstrated in favor of interventions guided by MMM. Clinical outcome may be improved with interventions guided by MMM. This strengthens the belief in this application, but further interdisciplinary collaborations are needed to overcome the heterogeneity, as illustrated in the present review. Future research should focus on increasing sample sizes, improved data collection, refining definitions of secondary injuries, and standardized interventions. Only then can we proceed with complex outcome studies with MMM-guided treatment.
KW - AIS
KW - ANEURYSMAL SUBARACHNOID HEMORRHAGE
KW - BLOOD-CELL TRANSFUSION
KW - EUROPEAN-SOCIETY
KW - FLOW
KW - HIBI
KW - ICH
KW - INTRAARTERIAL
KW - INTRACRANIAL-PRESSURE
KW - METABOLISM
KW - REACTIVITY
KW - SAH
KW - TBI
KW - TISSUE OXYGENATION
KW - VASOSPASM
KW - cerebral multimodality monitoring
KW - intensive care
KW - outcome
KW - Intensive care
KW - Hibi
KW - Tbi
KW - Cerebral multimodality monitoring
KW - Ais
KW - Ich
KW - Outcome
KW - Sah
U2 - 10.3389/fphys.2022.1071161
DO - 10.3389/fphys.2022.1071161
M3 - (Systematic) Review article
C2 - 36531179
SN - 1664-042X
VL - 13
JO - Frontiers in physiology
JF - Frontiers in physiology
M1 - 1071161
ER -